2 results
Approved WMOPending
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:• Reducing global disability in participants with acute ischemic stroke (AIS)
Approved WMORecruiting
We hypothesize that Kenalog-40, Kenalog-10 and Depo-Medrol 40 mg/ml have a different effectiveness in treating trigger fingers in both primary as secondary outcomes.